Childhood cancer survival in Europe 1999-2007

Results of EUROCARE-5-a population-based study

Gemma Gatta, Laura Botta, Silvia Rossi, Tiiu Aareleid, Magdalena Bielska-Lasota, Jacqueline Clavel, Nadya Dimitrova, Zsuzsanna Jakab, Peter Kaatsch, Brigitte Lacour, Sandra Mallone, Rafael Marcos-Gragera, Pamela Minicozzi, Maria José Sánchez-Pérez, Milena Sant, Mariano Santaquilani, Charles Stiller, Andrea Tavilla, Annalisa Trama, Otto Visser & 1 others Rafael Peris-Bonet

Research output: Contribution to journalArticle

318 Citations (Scopus)

Abstract

Background: Survival and cure rates for childhood cancers in Europe have greatly improved over the past 40 years and are mostly good, although not in all European countries. The EUROCARE-5 survival study estimates survival of children diagnosed with cancer between 2000 and 2007, assesses whether survival differences among European countries have changed, and investigates changes from 1999 to 2007. Methods: We analysed survival data for 157499 children (age 0-14 years) diagnosed between Jan 1, 1978 and Dec 31, 2007. They came from 74 population-based cancer registries in 29 countries. We calculated observed, country-weighted 1-year, 3-year, and 5-year survival for major cancers and all cancers combined. For comparison between countries, we used the corrected group prognosis method to provide survival probabilities adjusted for multiple confounders (sex, age, period of diagnosis, and, for all cancers combined without CNS cancers, casemix). Age-adjusted survival differences by area and calendar period were calculated with period analysis and were given for all cancers combined and the major cancers. Findings: We analysed 59579 cases. For all cancers combined for children diagnosed in 2000-07, 1-year survival was 90·6% (95% CI 90·2-90·9), 3-year survival was 81·0 % (95% CI 80·5-81·4), and 5-year survival was 77·9% (95% CI 77·4-78·3). For all cancers combined, 5-year survival rose from 76·1% (74·4-77·7) for 1999-2001, to 79·1% (77·3-80·7) for 2005-07 (hazard ratio 0·973, 95% CI 0·965-0·982, p

Original languageEnglish
Pages (from-to)35-47
Number of pages13
JournalThe Lancet Oncology
Volume15
Issue number1
DOIs
Publication statusPublished - Jan 2014

Fingerprint

Population
Neoplasms
Registries
Survival Rate
Demography

ASJC Scopus subject areas

  • Oncology

Cite this

Gatta, G., Botta, L., Rossi, S., Aareleid, T., Bielska-Lasota, M., Clavel, J., ... Peris-Bonet, R. (2014). Childhood cancer survival in Europe 1999-2007: Results of EUROCARE-5-a population-based study. The Lancet Oncology, 15(1), 35-47. https://doi.org/10.1016/S1470-2045(13)70548-5

Childhood cancer survival in Europe 1999-2007 : Results of EUROCARE-5-a population-based study. / Gatta, Gemma; Botta, Laura; Rossi, Silvia; Aareleid, Tiiu; Bielska-Lasota, Magdalena; Clavel, Jacqueline; Dimitrova, Nadya; Jakab, Zsuzsanna; Kaatsch, Peter; Lacour, Brigitte; Mallone, Sandra; Marcos-Gragera, Rafael; Minicozzi, Pamela; Sánchez-Pérez, Maria José; Sant, Milena; Santaquilani, Mariano; Stiller, Charles; Tavilla, Andrea; Trama, Annalisa; Visser, Otto; Peris-Bonet, Rafael.

In: The Lancet Oncology, Vol. 15, No. 1, 01.2014, p. 35-47.

Research output: Contribution to journalArticle

Gatta, G, Botta, L, Rossi, S, Aareleid, T, Bielska-Lasota, M, Clavel, J, Dimitrova, N, Jakab, Z, Kaatsch, P, Lacour, B, Mallone, S, Marcos-Gragera, R, Minicozzi, P, Sánchez-Pérez, MJ, Sant, M, Santaquilani, M, Stiller, C, Tavilla, A, Trama, A, Visser, O & Peris-Bonet, R 2014, 'Childhood cancer survival in Europe 1999-2007: Results of EUROCARE-5-a population-based study', The Lancet Oncology, vol. 15, no. 1, pp. 35-47. https://doi.org/10.1016/S1470-2045(13)70548-5
Gatta, Gemma ; Botta, Laura ; Rossi, Silvia ; Aareleid, Tiiu ; Bielska-Lasota, Magdalena ; Clavel, Jacqueline ; Dimitrova, Nadya ; Jakab, Zsuzsanna ; Kaatsch, Peter ; Lacour, Brigitte ; Mallone, Sandra ; Marcos-Gragera, Rafael ; Minicozzi, Pamela ; Sánchez-Pérez, Maria José ; Sant, Milena ; Santaquilani, Mariano ; Stiller, Charles ; Tavilla, Andrea ; Trama, Annalisa ; Visser, Otto ; Peris-Bonet, Rafael. / Childhood cancer survival in Europe 1999-2007 : Results of EUROCARE-5-a population-based study. In: The Lancet Oncology. 2014 ; Vol. 15, No. 1. pp. 35-47.
@article{647ea4c2c2f24381bb49f596bee5786f,
title = "Childhood cancer survival in Europe 1999-2007: Results of EUROCARE-5-a population-based study",
abstract = "Background: Survival and cure rates for childhood cancers in Europe have greatly improved over the past 40 years and are mostly good, although not in all European countries. The EUROCARE-5 survival study estimates survival of children diagnosed with cancer between 2000 and 2007, assesses whether survival differences among European countries have changed, and investigates changes from 1999 to 2007. Methods: We analysed survival data for 157499 children (age 0-14 years) diagnosed between Jan 1, 1978 and Dec 31, 2007. They came from 74 population-based cancer registries in 29 countries. We calculated observed, country-weighted 1-year, 3-year, and 5-year survival for major cancers and all cancers combined. For comparison between countries, we used the corrected group prognosis method to provide survival probabilities adjusted for multiple confounders (sex, age, period of diagnosis, and, for all cancers combined without CNS cancers, casemix). Age-adjusted survival differences by area and calendar period were calculated with period analysis and were given for all cancers combined and the major cancers. Findings: We analysed 59579 cases. For all cancers combined for children diagnosed in 2000-07, 1-year survival was 90·6{\%} (95{\%} CI 90·2-90·9), 3-year survival was 81·0 {\%} (95{\%} CI 80·5-81·4), and 5-year survival was 77·9{\%} (95{\%} CI 77·4-78·3). For all cancers combined, 5-year survival rose from 76·1{\%} (74·4-77·7) for 1999-2001, to 79·1{\%} (77·3-80·7) for 2005-07 (hazard ratio 0·973, 95{\%} CI 0·965-0·982, p",
author = "Gemma Gatta and Laura Botta and Silvia Rossi and Tiiu Aareleid and Magdalena Bielska-Lasota and Jacqueline Clavel and Nadya Dimitrova and Zsuzsanna Jakab and Peter Kaatsch and Brigitte Lacour and Sandra Mallone and Rafael Marcos-Gragera and Pamela Minicozzi and S{\'a}nchez-P{\'e}rez, {Maria Jos{\'e}} and Milena Sant and Mariano Santaquilani and Charles Stiller and Andrea Tavilla and Annalisa Trama and Otto Visser and Rafael Peris-Bonet",
year = "2014",
month = "1",
doi = "10.1016/S1470-2045(13)70548-5",
language = "English",
volume = "15",
pages = "35--47",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "1",

}

TY - JOUR

T1 - Childhood cancer survival in Europe 1999-2007

T2 - Results of EUROCARE-5-a population-based study

AU - Gatta, Gemma

AU - Botta, Laura

AU - Rossi, Silvia

AU - Aareleid, Tiiu

AU - Bielska-Lasota, Magdalena

AU - Clavel, Jacqueline

AU - Dimitrova, Nadya

AU - Jakab, Zsuzsanna

AU - Kaatsch, Peter

AU - Lacour, Brigitte

AU - Mallone, Sandra

AU - Marcos-Gragera, Rafael

AU - Minicozzi, Pamela

AU - Sánchez-Pérez, Maria José

AU - Sant, Milena

AU - Santaquilani, Mariano

AU - Stiller, Charles

AU - Tavilla, Andrea

AU - Trama, Annalisa

AU - Visser, Otto

AU - Peris-Bonet, Rafael

PY - 2014/1

Y1 - 2014/1

N2 - Background: Survival and cure rates for childhood cancers in Europe have greatly improved over the past 40 years and are mostly good, although not in all European countries. The EUROCARE-5 survival study estimates survival of children diagnosed with cancer between 2000 and 2007, assesses whether survival differences among European countries have changed, and investigates changes from 1999 to 2007. Methods: We analysed survival data for 157499 children (age 0-14 years) diagnosed between Jan 1, 1978 and Dec 31, 2007. They came from 74 population-based cancer registries in 29 countries. We calculated observed, country-weighted 1-year, 3-year, and 5-year survival for major cancers and all cancers combined. For comparison between countries, we used the corrected group prognosis method to provide survival probabilities adjusted for multiple confounders (sex, age, period of diagnosis, and, for all cancers combined without CNS cancers, casemix). Age-adjusted survival differences by area and calendar period were calculated with period analysis and were given for all cancers combined and the major cancers. Findings: We analysed 59579 cases. For all cancers combined for children diagnosed in 2000-07, 1-year survival was 90·6% (95% CI 90·2-90·9), 3-year survival was 81·0 % (95% CI 80·5-81·4), and 5-year survival was 77·9% (95% CI 77·4-78·3). For all cancers combined, 5-year survival rose from 76·1% (74·4-77·7) for 1999-2001, to 79·1% (77·3-80·7) for 2005-07 (hazard ratio 0·973, 95% CI 0·965-0·982, p

AB - Background: Survival and cure rates for childhood cancers in Europe have greatly improved over the past 40 years and are mostly good, although not in all European countries. The EUROCARE-5 survival study estimates survival of children diagnosed with cancer between 2000 and 2007, assesses whether survival differences among European countries have changed, and investigates changes from 1999 to 2007. Methods: We analysed survival data for 157499 children (age 0-14 years) diagnosed between Jan 1, 1978 and Dec 31, 2007. They came from 74 population-based cancer registries in 29 countries. We calculated observed, country-weighted 1-year, 3-year, and 5-year survival for major cancers and all cancers combined. For comparison between countries, we used the corrected group prognosis method to provide survival probabilities adjusted for multiple confounders (sex, age, period of diagnosis, and, for all cancers combined without CNS cancers, casemix). Age-adjusted survival differences by area and calendar period were calculated with period analysis and were given for all cancers combined and the major cancers. Findings: We analysed 59579 cases. For all cancers combined for children diagnosed in 2000-07, 1-year survival was 90·6% (95% CI 90·2-90·9), 3-year survival was 81·0 % (95% CI 80·5-81·4), and 5-year survival was 77·9% (95% CI 77·4-78·3). For all cancers combined, 5-year survival rose from 76·1% (74·4-77·7) for 1999-2001, to 79·1% (77·3-80·7) for 2005-07 (hazard ratio 0·973, 95% CI 0·965-0·982, p

UR - http://www.scopus.com/inward/record.url?scp=84891372811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891372811&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(13)70548-5

DO - 10.1016/S1470-2045(13)70548-5

M3 - Article

VL - 15

SP - 35

EP - 47

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 1

ER -